Madison Investment Advisors LLC Takes $4.59 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Madison Investment Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 6,445 shares of the biopharmaceutical company’s stock, valued at approximately $4,591,000.

Several other large investors also recently added to or reduced their stakes in REGN. Thrivent Financial for Lutherans raised its stake in Regeneron Pharmaceuticals by 16.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company’s stock valued at $9,587,000 after purchasing an additional 1,306 shares during the period. Prospera Financial Services Inc acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $778,000. PNC Financial Services Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company’s stock valued at $19,264,000 after purchasing an additional 153 shares during the period. Integrated Investment Consultants LLC raised its stake in Regeneron Pharmaceuticals by 85.1% during the 3rd quarter. Integrated Investment Consultants LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 262 shares during the period. Finally, Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 18.7% during the 3rd quarter. Pacer Advisors Inc. now owns 19,540 shares of the biopharmaceutical company’s stock valued at $20,541,000 after purchasing an additional 3,076 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN stock opened at $658.48 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a 50-day moving average of $689.43 and a two-hundred day moving average of $818.17. The stock has a market capitalization of $71.99 billion, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company earned $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. TD Cowen dropped their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.